Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Martí Carvajal, Arturo J ^a   Anand, Vidhu ^b   Solà, Ivan ^c  

^a Iberoamerican Cochrane Network   (Venezuela)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; DANAPAROID; DERMATAN SULFATE; DROTRECOGIN; HEPARIN; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TRANEXAMIC ACID; PROTEIN C; THROMBOMODULIN;

ACUTE LEUKEMIA; ANTIBIOTIC THERAPY; BLEEDING; BLEEDING TENDENCY; BLOOD TRANSFUSION; CHRONIC LEUKEMIA; DISSEMINATED INTRAVASCULAR CLOTTING; ECCHYMOSIS; FLUID THERAPY; HEMATURIA; HOSPITAL MORTALITY; HUMAN; ITALY; JAPAN; MEASUREMENT; MUCOSAL BLEEDING; NETHERLANDS; PETECHIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SENSITIVITY ANALYSIS; SKIN BLEEDING; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; BLOOD; CHRONIC DISEASE; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; LEUKEMIA; META ANALYSIS;

ACUTE DISEASE; ANTICOAGULANTS; CHRONIC DISEASE; DERMATAN SULFATE; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; LEUKEMIA; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOMODULIN; TRANEXAMIC ACID;

EID: 84957792619     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008562.pub3     Document Type: Review

References (149)

1. Aoki N, Matsuda T, Saito H, Takatsuki K, Okajima K, Takahashi H, et al. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology 2002;75(5):540-7. [PUBMED: 12095157]
2. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011;35(4):349-54. [PUBMED: 21068698]
3. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double-blind, clinical trial [Abstract No. 576]. Blood 2006;108(11 Part 1):174. [: CN-00624858]
4. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. Journal of Thrombosis and Hemostasis 2007;5(1):31-41. [PUBMED: 17059423]
5. Avvisati G, ten Cate JW, Büller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989;2(8655):122-4. [PUBMED: 2567893]
6. Cofrancesco E, Boschetti C, Leonardi P, Cortellaro M. A randomized, heparin (H)-controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research 1993;70(Suppl 1):74.
7. Cofrancesco E, Boschetti C, Leonardi P, Cortellaro M. Dermatan sulphate in acute leukaemia. Lancet 1992;339(8802):1177-8. [PUBMED: 1349404]
8. Cofrancesco E, Boschetti C, Leonardi P, Gianese F, Cortellaro M. Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin-controlled pilot study. Thrombosis Research 1994;74(1):65-75. [PUBMED: 8029809]
9. Aoki N, Hirosawa S, Kurosawa S, Matsuda T, Saito H, Takamatsu J, et al. Clinical evaluation of low molecular weight heparin preparation (LHN-1) on disseminated intravascular coagulation (DIC): multicenter phase II clinical study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1994;10(12):2629-65.
10. Asakura H, Takahashi H, Tsuji H, Matsushita T, Ninomiya H, Honda G, et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1, 032 patients with hematologic malignancy. Thrombosis Research 2014;133(3):364-70.
11. Aviles de la Garza R, Perez Tamayo R, Becker Fause I, Linares Ponton G, Anaya Galindo R. Intravascular disseminated coagulation. Critical analysis of a 5 years experience at the Instituto Nacional de la Nutrición Salvador Zubirán (Mexico) [Coagulación intravascular diseminada. Análisis crítico de la experiencia del Instituto Nacional de la Nutricion Salvador Zubirán en 5 años]. Revista de Investigación Clínica 1982;34(4):307-12. [: 13075 (LILACS)]
12. Chojnowski K, Trelinski J, Wawrzyniak E, Robak T. The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy--report of a prospective randomized study. Leukemia & Lymphoma 2002;43(5):1021-8. [PUBMED: 12148881]
13. Fourrier F, Chopin C, Huart J J, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104(3):882-8. [PUBMED: 8365305]
14. Franchini M, Manzato F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagulation & Fibrinolysis 2007;18(7):589-93. [PUBMED: 17890943]
15. Gamba G, Grignani G, Biancardi M, Geroldi D, Ascari E. Acute leukemias and D.I.C.: effectiveness of treatment with low doses of heparin. Haematologica 1979;64(3):322-30. [PUBMED: 113300]
16. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care 2013;17(6):R297. [PUBMED: 24342495]
17. Gillis S, Dann EJ, Eldor A. Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia. European Journal of Hematology 1995;54(1):59-60. [PUBMED: 7859878]
18. Gralnick HR, Bagley J, Abrell E. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. American Journal of Medicine 1972;52(2):167-74. [PUBMED: 4500954]
19. Göbel U, von Voss H, Jurgens H, Petrich C, Pothmann R, Sprock I, et al. Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation. European Journal of Pediatrics 1980;133(1):47-9. [PUBMED: 7353570]
20. Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood 1987;69(1):187-91. [PUBMED: 3466655]
21. Gross SJ, Filston HC, Anderson JC. Controlled study of treatment for disseminated intravascular coagulation in the neonate. Journal of Pediatrics 1982;100(3):445-8. [PUBMED: 7038076]
22. Hoffmann JN, Mühlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine 2004;32(9):1851-9. [PUBMED: 15343012]
23. Hofmann M, Rest A, Hafner G, Tanner B, Brockerhoff P, Weilemann LS. Evaluation of coagulation and fibrinolytics parameters in the therapeutic management of disseminated intravascular coagulation with sepsis by low molecular weight/heparin [German]. Der Anaesthesist 1997;46(8):689-96. [PUBMED: 9382207]
24. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thrombosis Research 2012;130(3):e129-33. [PUBMED: 22542365]
25. Ikezoe T, Takeuchi A, Isaka M, Arakawa Y, Iwabu N, Kin T, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leukemia Research 2012;36(11):1398-402. [PUBMED: 22917769]
26. Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thrombosis Journal 2013;11(1):3. [PUBMED: 23414216]
27. Kawano N, Kuriyama T, Yoshida S, Yamashita K, Ochiai H, Nakazaki S, et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Internal Medicine 2013;52(1):55-62. [PUBMED: 23291674]
28. Kawano N, Tasaki A, Kuriyama T, Tahara Y, Yoshida S, Ono N, et al. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution--an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases. Internal Medicine 2014;53(3):205-13. [PUBMED: 24492688]
29. Kawano N, Yoshida S, Ono N, Himeji D, Nagahiro Y, Sayaka K, et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. Journal of Clinical and Experimental Hematopathology 2011;51(2):101-7. [PUBMED: 22104308]
30. Koseki M, Asada N, Uryu H, Takeuchi M, Asakura H, Matsue K. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. International Journal of Hematology 2007;86(5):403-6. [PUBMED: 18192107]
31. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis 2006;4(1):90-7. [PUBMED: 16409457]
32. Liu XL, Wang XZ, Liu XX, Hao D, Jaladat Y, Lu F, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Experimental and Therapeutic Medicine 2014;7(3):604-8. [PUBMED: 24520253]
33. Martínez López I, Jiménez Armada J, Ballmajó Real M, Sánchez García RW, Solano Rolando M. Fulminant disseminated intravascular coagulation in a patient with acute promyelocytic leukaemia [Coagulación intravascular diseminada fulminante en una paciente con leucemia promielocítica aguda]. Revista Cubana de Medicina 2002;4(1):303-7. [: 354369 (LILACS)]
34. Matsushita T, Watanabe J, Honda G, Mimuro J, Takahashi H, Tsuji H, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thrombosis Research 2014;133(5):772-81. [PUBMED: 24636871]
35. Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer 1986;58(3):761-4. [PUBMED: 2425925]
36. Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. American Journal of Emergency Medicine 2012;30(7):1219-23. [PUBMED: 22204993]
37. Nowrousian MR, Hilgard P. Low-dose heparin in the management of acute myelocytic leukaemia. Blut 1978;37(6):341-3. [PUBMED: 281971]
38. Ogawa E, Yagasaki H, Kato M, Shichino H, Chin M, Mugishima H. Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin. British Journal of Haematology 2010;149(6):911-2. [PUBMED: 20346017]
39. Oguma Y, Sakuragawa N, Maki M, Hasegawa H, Nakagawa M. Treatment of disseminated intravascular coagulation with low molecular weight heparin. Research Group of FR-860 on DIC in Japan. Seminars in Thrombosis and Hemostasis 1990;16 Suppl:34-40. [PUBMED: 1962902]
40. Oguma Y, Sakuragawa N, Maki M, Nakagawa M, Hasegawa H. Clinical effect of low molecular weight heparin (fragmin) on DIC: a multicenter cooperative study in Japan. Thrombosis Research 1990;59(1):37-49. [PUBMED: 2169078]
41. Pizzuto J, Gonzalez Llaven J, Uribe Cortes JA. Heparin as treatment for hypercoagulability syndrome in a case of acute promyelocytic leukemia [Spanish]. Sangre 1969;14(3):363-70. [PUBMED: 5288844]
42. Pogliani EM, Salvatore M, Masera G, Corneo G. Antifibrinolytic therapy in acute promyelocytic leukemia. Acta Haematologica 1989;81(1):58-9. [PUBMED: 2494837]
43. Rodríguez Gómez M, López Fernández MF, Batlle J. Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases [Terapéutica de la coagulación intravascular diseminada en las leucemias agudas promielocíticas. A propósito de 19 casos]. Sangre 1993;38(6):449-53. [PUBMED: 8171380]
44. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Morishita E, et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagulation & Fibrinolysis 1995;6(1):60-4. [PUBMED: 7540878]
45. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC): a multicenter cooperative double-blind trial in comparison with heparin. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1992;8(2):423-52.
46. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter co-operative double-blind trial in comparison with heparin. Thrombosis Research 1993;72(6):475-500. [PUBMED: 8128454]
47. Sandler RM, Liebman HA, Patch MJ, Teitelbaum A, Levine AM, Feinstein DI. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin. Cancer 1982;50(10):2106-10. [PUBMED: 6957257]
48. Sandler RM, Liebman HA, Patch MJ, Teitelbaum A, Levine AM, Feinstein DI. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin. Cancer 1983;51(4):681-5. [PUBMED: 6571800]
49. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clinical and Applied Thrombosis/Hemostasis 2009;15(5):561-6. [PUBMED: 18840625]
50. Shindo M, Ikuta K, Addo L, Ito S, Fujiya M, Torimoto Y, et al. Successful control of disseminated intravascular coagulation by recombinant thrombomodulin during arsenic trioxide treatment in relapsed patient with acute promyelocytic leukemia. Case Reports in Hematology 2012;2012:908196. [PUBMED: 23008787]
51. Shirahata A, Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, et al. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. European Journal of Pediatrics 2014;173(3):303-11. [PUBMED: 24005342]
52. Shpilberg O, Blumenthal R, Sofer O, Eldor A, Ben Bassat I. A controlled trial of tranexamic acid (TA) treatment for reduction of bleeding during acute myeloid leukemia (AML) induction and consolidation. Blood 1993;82(10 Suppl 1):547a. [: CN-00461734]
53. Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leukemia & Lymphoma 1995;19(1-2):141-4. [PUBMED: 8574160]
54. Sugawara T, Okuda M, Yamaguchi Y, Endo K, Yoshinaga K. Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia. Acta Haematologica 1992;87(1-2):109. [PUBMED: 1585765]
55. Takagi K, Tasaki T, Yamauchi T, Iwasaki H, Ueda T. Successful administration of recombinant human soluble thrombomodulin (Recomodulin) for disseminated intravascular coagulation during induction chemotherapy in an elderly patient with acute monoblastic leukemia involving the t(9;11)(p22;q23) MLL/AF9 translocation. Case Reports in Hematology 2011;2011:273070. [PUBMED: 22937304]
56. Takezako N, Sekiguchi N, Noto S, Ogino Y, Miwa A, Ikezoe T. Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: Results of a multicenter, retrospective epidemiologic study in Japan. Blood. 2014; Vol. 124:2875. [: CN-01049686]
57. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Seminars in Thrombosis and Hemostasis 1989;15(3):347-52. [PUBMED: 2688106]
58. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Critical Care Medicine 2013;41(9):2069-79. [PUBMED: 23979365]
59. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thrombosis and Haemostasis 1995;74(3):848-52. [PUBMED: 8571309]
60. Walia SS, Walia HS. Therapeutic interventions in endotoxin-induced disseminated intravascular coagulation. Journal of Natural Science, Biology, and Medicine 2012;3(1):108-9. [PUBMED: 22690065]
61. Yamaguchi M, Murata R, Mizutani T, Kawamura Y, Ueda M. Acute myelogenous leukemia associated with disseminated intravascular coagulation and acute myocardial infarction at relapse [Japanese]. Rinsho Ketsueki (Japanese Journal of Clinical Haematology) 2001;42(9):716-8. [PUBMED: 11680986]
62. Yamato M, Minematsu Y, Fujii J, Mori K, Minato T, Miyagawa S, et al. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial. Therapeutic Apheresis and Dialysis 2013;17(5):472-6. [PUBMED: 24107274]
63. Yang H, Zhu CY, Wang QS, Niu JH, Zhang Q, Zhu HY, et al. Analysis of empirical treatment for newly diagnosed acute promyelocytic leukemia combined with disseminated intravascular coagulation [Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi/Zhongguo Bing li Sheng li Xue hui/Journal of Experimental Hematology/Chinese Association of Pathophysiology 2014;22(2):315-22. [PUBMED: 24762998]
64. Yin Q, Li C. Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation. Evidence-based Complementary and Alternative Medicine 2014;2014:949254. [PUBMED: 24778706]
65. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis 2004;2(6):899-909. [PUBMED: 15140125]
66. Asthana B, Sharma P, Ranjan R, Jain P, Aravindan A, Chandra Mishra P, et al. Patterns of acquired bleeding disorders in a tertiary care hospital. Clinical and Applied Thrombosis/Hemostasis 2009;15(4):448-53. [PUBMED: 19520680]
67. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Seminars in Thrombosis and Hemostasis 2001;27(6):593-604. [PUBMED: 11740683]
68. Brunton L, Parker K, Blumenthal D, Buxton I. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Brunton L, Parker K, Blumenthal D, Buxton I editor(s). Goodman & Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw-Hill Companies, Inc, 2008:949-66. [DOI: 10.1036/0071443436]
69. Bunjevacki G, Sultan Y, Izraël V. [Disseminated intravascular coagulation (D.I.C.) and fibrinolysis in patients with acute leukemia (author's transl)] [Coagulation intravasculaire disséminée et fibrinolyse au cours des leucemies aiguës]. Nouvelle Revue Française d'Hématologie 1978;20(4):575-84. [PUBMED: 752151]
70. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews. Neuroscience 2013;14(5):365-76. [PUBMED: 23571845]
71. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013;309(8):814-22. [PUBMED: 23443445]
72. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, at al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. [PUBMED: 23303884]
73. Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. American Journal of Hematology 2012;87(6):596-603. [PUBMED: 22549696]
74. Chu AJ. Biochemical strategies to anticoagulation: a comparative overview. Current Vascular Pharmacology 2004;2(3):199-228. [PUBMED: 15320820]
75. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39. [PUBMED: 18039365]
76. Martin E. Concise Medical Dictionary. 8th Edition. New York: Oxford University Press, 2011.
77. Cornell RF, Palmer J. Adult acute leukemia. Disease-a-Month 2012;58(4):219-38. [PUBMED: 22449370]
78. Dalainas I. Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. European Review for Medical and Pharmacological Sciences 2008;12(1):19-31. [PUBMED: 18401969]
79. DeLoughery TG. Critical care clotting catastrophies. Critical Care Clinics 2005;21(3):531-62. [PUBMED: 15992672]
80. Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clinical and Applied Thrombosis/Hemostasis 2007;13(3):292-8. [PUBMED: 17636191]
81. Dmoszyńska A. Intravascular disseminated coagulation syndrome in patients with acute leukemias [Zespol rozsianego krzepniecia srodnaczyniowego u chorych na ostre bialaczki]. Acta Haematologica Polonica 1976;7(2):139-46. [PUBMED: 1065178]
82. Dorantes-Acosta E, Medina-Sanson A, Jaimes-García Y, López-Martínez B. Clinical features and treatment outcomes of pediatric acute promyelocytic leukemia in a Mexican pediatric hospital. Revista de Investigación Clínica 2013;65(5):392-8. [PUBMED: 24687338]
83. Draper M. Which database should I use?. https://www.adelaide.edu.au/library/guide/med/wd.html (accessed 29 September 2014).
84. Dreyfus B, Varet B, Heilmann-Gouault M, Sultan C, Reyes F, Gluckman E, et al. The treatment of disseminated intravascular coagulation in 18 cases of promyelocytic acute leukaemia (author's translation) [Traitement dans 18 observations de leucémies aiguës promyélocytaires de la coagulation intravasculaire disséminée]. Nouvelle Revue Française d'Hématologie 1973;13(6):761-70. [PUBMED: 4280042]
85. Durán Suárez JR, Juncá Piera J, Zuazu Nagore J, Triginer Boixeda JM. Disseminated intravascular coagulation as the presenting feature of lymphoblastic leukemia. Study of a case [Coagulación intravascular diseminada como forma de presentación de leucosis linfoblástica. Estudio de un caso]. Medicina Clínica 1980;75(9):391-3. [PUBMED: 6936572]
86. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Reviews. Immunology 2013;13(1):34-45. [PUBMED: 23222502]
87. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Practice & Research. Clinical Haematology 2003;16(3):463-82. [PUBMED: 12935963]
88. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thrombosis Journal 2006;4:4. [PUBMED: 16504043]
89. Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Seminars in Thrombosis and Hemostasis 2010;36(4):388-403. [PUBMED: 20614391]
90. Fujiwara H, Takahashi N, Tada J, Higuchi T, Harada H, Mori H, et al. Blast crisis accompanied by severe DIC of Ph negative chronic myeloid leukemia showing t(9;16) and positive M-BCR/ABL rearrangement [Japanese]. Rinsho Ketsueki 1997;38(8):663-8. [PUBMED: 9311272]
91. García de Paredes ML, González Larriba JL, Ordoñez Gallego A, Martínez Martínez B, Montero García JM. Disseminated intravascular coagulation as the 1st manifestation of a chronic myeloid leukemia [Spanish]. Medicina Clínica (Barc) 1983;81(8):369-70. [PUBMED: 6580521]
92. German HJ, Smith JA, Lindenbaum J. Chronic intravascular coagulation associated with chronic myelocytic leukemia. Use of heparin in connection with a surgical procedure. American Journal of Medicine 1976;61(4):547-52. [PUBMED: 1067753]
93. Gingrich RD, Burns CP. Disseminated coagulopathy in chronic myelomonocytic leukemia. Cancer 1979;44(6):2249-53. [PUBMED: 292510]
94. Brozek J, Oxman A, Schünemann H. Grading of Recommendations Assessment, Development and Evaluation (GRADE). 3.2. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, 2008.
95. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice. Circulation 2001;103(10):1479-84. [PUBMED: 11245656]
96. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, and GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [PUBMED: 18436948]
97. Hess EP, Sztajnkrycer MD. Images in emergency medicine. Acute leukemia with blast crisis, disseminated intravascular coagulation, and intraparenchymal hemorrhage. Annals of Emergency Medicine 2005;46(4):314, 322. [PUBMED: 16187462]
98. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [PUBMED: 12958120]
99. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
100. Higuchi T, Toyama D, Hirota Y, Isoyama K, Mori H, Niikura H, et al. Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases. Leukemia & Lymphoma 2005;46(8):1169-76. [PUBMED: 16085558]
101. Hoffman R. Hematology. Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone, 2008. [: ISBN: 978-0-443-06715-0]
102. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [PUBMED: 10480822]
103. Hook KM, Abrams CS. The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients. Clinical and Translational Science 2012;5(1):85-92. [PUBMED: 22376264]
104. Hopewell S, Clarke M, Higgins JPT (editors). Core reporting of outcomes in effectiveness trials. Cochrane Methods. Cochrane Database of Systematic Reviews 2010;Suppl 1:1-29. [: ISSN 2044-4702]
105. Hoyle CF, Swirsky DM, Freedman L, Hayhoe FG. Beneficial effect of heparin in the management of patients with APL. British Journal of Haematology 1988;68(3):283-9. [PUBMED: 3162683]
106. Hunt BJ. Bleeding and coagulopathies in critical care. New England Journal of Medicine 2014;370(9):847-59. [PUBMED: 24571757]
107. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thrombosis Research 2013;131(5):383-9. [PUBMED: 23566533]
108. International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
109. Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. International Journal of Hematology 2014;100(1):27-37. [PUBMED: 24217998]
110. Ioannidis JP. Meta-research: The art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
111. Tokuhira M. Clinical efficacy of thrombomodulin alfa in hematological malignancy with disseminated intravascular coagulation. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000006738 (accessed 29 September 2014).
112. Yokoyama H. Clinical study on the efficacy of recombinant thrombomodulin for DIC complicated with acute leukemia. http://www.umin.ac.jp/ctr/index.htm (accessed 29 September 2014).
113. Kaiser B, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs 2001;10(11):1925-35. [PUBMED: 11772296]
114. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PUBMED: 20156912]
115. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [PUBMED: 11730399]
116. Komatsu N, Yoshida N, Tsuboyama A, Sato Y, Sakamoto S, Miura Y. Promyelocytic crisis of chronic myelogenous leukemia: coagulopathy similar to atypical disseminated intravascular coagulation in acute promyelocytic leukemia. Nippon Ketsueki Gakkai Zasshi 1986;49(4):894-9. [PUBMED: 3464156]
117. Kwaan HC. The unique hemostatic dysfunction in acute promyelocytic leukemia. Seminars in Thrombosis and Hemostasis 2014;40(3):332-6. [PUBMED: 24590422]
118. Levi M. Disseminated intravascular coagulation. Critical Care Medicine 2007;35(9):2191-5. [PUBMED: 17855836]
119. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Seminars in Thrombosis and Hemostasis 2008;34(5):459-68. [PUBMED: 18956286]
120. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology 2009;145(1):24-33. [PUBMED: 19222477]
121. Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Internal and Emergency Medicine 2013;8(1):23-32. [PUBMED: 23015284]
122. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Seminars in Oncology 2008;35(4):401-9. [PUBMED: 18692690]
123. Mangal AK, Grossman L, Vickars L. Disseminated intravascular coagulation in acute monoblastic leukemia: response to heparin therapy. Canadian Medical Association Journal 1984;130(6):731-3. [PUBMED: 6582992]
124. Nowak G. Pharmacology of recombinant hirudin. Seminars in Thrombosis and Hemostasis 2002;28(5):415-24. [PUBMED: 12420236]
125. Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. American Journal of Hematology 2000;65(3):215-22. [PUBMED: 11074538]
126. Pal N, Kertai MD, Lakshminarasimhachar A, Avidan MS. Pharmacology and clinical applications of human recombinant antithrombin. Expert Opinion on Biological Therapy 2010;10(7):1155-68. [PUBMED: 20528611]
127. Patient-Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient-centered outcomes research". http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf (accessed 1 April 2013):1-61.
128. Porta M. A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008.
129. Prentice CR. Acquired coagulation disorders. Clinics in Haematology 1985;14(2):413-42. [PUBMED: 3899441]
130. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
131. Rosenthal NS, Knapp D, Farhi DC. Promyelocytic blast crisis of chronic myelogenous leukemia. A rare subtype associated with disseminated intravascular coagulation. American Journal of Clinical Pathology 1995;103(2):185-8. [PUBMED: 7856560]
132. Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992;79(5):1305-10. [PUBMED: 1536954]
133. Savović J, Jones H, Altman D, Harris R, Jüni P, Pildal J. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38. [PUBMED: 22945832]
134. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010;152(11):726-32. [PUBMED: 20335313 ]
135. Seligman BR, Rosner F, Solomon RB. Chronic myelogenous leukemia. Disseminated intravascular coagulation and chloromas containing sea-blue histiocytes. New York State Journal of Medicine 1975;75(8):1271-4. [PUBMED: 1055903]
136. Speiser W, Pabinger-Fasching I, Kyrle PA, Kapiotis S, Kottas-Heldenberg A, Bettelheim P, et al. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut 1990;61(5):298-302. [PUBMED: 2271776]
137. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Practice & Research. Clinical Haematology 2009;22(1):153-63. [PUBMED: 19285282]
138. Sunder-Plassmann G, Speiser W, Korninger C, Stain M, Bettelheim P, Pabinger-Fasching I, et al. Disseminated intravascular coagulation and decrease in fibrinogen levels induced by vincristine/prednisolone therapy of lymphoid blast crisis of chronic myeloid leukemia. Annals of Hematology 1991;62(5):169-73. [PUBMED: 2049463]
139. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One 2011;6(10):e25491. [PUBMED: 22028777]
140. Tsukagoshi S. Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation [Japanese]. Gan to Kagaku Ryoho. Cancer and Chemotherapy 2000;27(5):767-74. [PUBMED: 10832450]
141. Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. International Journal of Hematology 2007;86(2):137-42. [PUBMED: 17875527]
142. van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thrombosis and Haemostasis 2014;112(4):640-8. [PUBMED: 24696161]
143. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thrombosis Research 2010;125(1):6-11. [PUBMED: 19782389]
144. Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: testing and diagnosis. Clinica Chimica Acta 2014;436:130-4. [PUBMED: 24792730]
145. Williams J, Mozurkewich E, Chilimigras J, Van De Ven C. Critical care in obstetrics: pregnancy-specific conditions. Best Practice & Research. Clinical Obstetrics & Gynaecology 2008;22(5):825-46. [PUBMED: 18775679]
146. Yanada M, Matsushita T, Suzuki M, Kiyoi H, Yamamoto K, Kinoshita T, et al. Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation. European Journal of Haematology 2006;77(4):282-7. [PUBMED: 16856920]
147. Yoshikawa H, Maruo K. Blastic crisis of a chronic myelogenous leukemia with disseminated intravascular coagulation, with special reference to "AAAP" therapy (author's translation) [Japanese]. Rinsho Ketsueki [Japanese Journal of Clinical Hematology] 1980;21(1):52-8. [PUBMED: 6929365]
148. Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián G. Data extraction sheet to help manage the characteristics of included studies in Cochrane reviews. Valencia, Venezuela: Universidad de Carabobo, 2006.
149. Marti-Carvajal AJ, Simancas D, Cardona AF. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2]